BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28779136)

  • 1. Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma.
    Wei X; Choudhury Y; Lim WK; Anema J; Kahnoski RJ; Lane B; Ludlow J; Takahashi M; Kanayama HO; Belldegrun A; Kim HL; Rogers C; Nicol D; Teh BT; Tan MH
    Sci Rep; 2017 Aug; 7(1):7342. PubMed ID: 28779136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
    Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.
    Hakimi AA; Chen YB; Wren J; Gonen M; Abdel-Wahab O; Heguy A; Liu H; Takeda S; Tickoo SK; Reuter VE; Voss MH; Motzer RJ; Coleman JA; Cheng EH; Russo P; Hsieh JJ
    Eur Urol; 2013 May; 63(5):848-54. PubMed ID: 23036577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and prognostic value of CEP55 in clear cell renal cell carcinoma as determined by bioinformatics analysis.
    Zhou L; Liu S; Li X; Yin M; Li S; Long H
    Mol Med Rep; 2019 May; 19(5):3485-3496. PubMed ID: 30896867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
    Kapur P; Peña-Llopis S; Christie A; Zhrebker L; Pavía-Jiménez A; Rathmell WK; Xie XJ; Brugarolas J
    Lancet Oncol; 2013 Feb; 14(2):159-167. PubMed ID: 23333114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
    Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
    BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
    Brugarolas J
    Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With
    Liu Y; Li Y; Xu H; Zhou L; Yang X; Wang C
    Int J Surg Pathol; 2023 Dec; 31(8):1485-1494. PubMed ID: 36911986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap.
    Shi B; Ding J; Qi J; Gu Z
    Int J Med Sci; 2021; 18(9):2063-2075. PubMed ID: 33850477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma.
    Shen C; Liu J; Wang J; Zhong X; Dong D; Yang X; Wang Y
    Int Immunopharmacol; 2020 Apr; 81():106274. PubMed ID: 32044664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
    Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
    Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
    Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group.
    Shinagare AB; Vikram R; Jaffe C; Akin O; Kirby J; Huang E; Freymann J; Sainani NI; Sadow CA; Bathala TK; Rubin DL; Oto A; Heller MT; Surabhi VR; Katabathina V; Silverman SG
    Abdom Imaging; 2015 Aug; 40(6):1684-92. PubMed ID: 25753955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma.
    Köhn L; Svenson U; Ljungberg B; Roos G
    Appl Immunohistochem Mol Morphol; 2015; 23(5):334-42. PubMed ID: 24992170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.